|Bid||179.02 x 900|
|Ask||179.37 x 2200|
|Day's Range||177.39 - 180.00|
|52 Week Range||136.50 - 186.44|
|PE Ratio (TTM)||110.83|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||196.52|
Vertex Pharmaceuticals Incorporated (VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET. The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). Ms. Jensen will also serve as the Executive Director of The Vertex Foundation, a 501(c)(3) organization and long-term source of charitable giving. “Vertex is deeply committed to patients, communities and stakeholders as evidenced by its 10-year corporate giving commitment and creation of The Vertex Foundation,” said Ms. Jensen.
Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.
Bluebird Bio (BLUE) is a clinical stage biotechnology company. It reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline YoY (year-over-year) compared to $16.72 million in the second quarter of 2017.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
-Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F5
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
CRISPR Therapeutics might lead its start-up peers, but its collaboration partner is the better stock to buy.
An apple a day may keep the doctor away, as the old saying goes, but Apple's strong gains on a near-daily basis have not kept away buyable stocks from the health care sector.
Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.
Vertex Pharmaceuticals (Europe) Limited announces finalization of an agreement with the Australian Government that allows for reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for people ages six and over with cystic fibrosis (CF) who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This agreement means lumacaftor/ivacaftor will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 October and follows a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC).
Vertex Pharmaceuticals Inc.’s cystic fibrosis medicine Orkambi will be subsidized by the Australian government from next month. The medicine will be available on the Pharmaceutical Benefits Scheme from Oct. 1 for all patients over the age of six who have the most common form of cystic fibrosis, Prime Minister Scott Morrison said in a statement Sunday. “This will provide over 1,200 Australian patients, and their families, with a longer and better life,” Morrison said, adding Vertex had agreed to provide “compassionate free access” until the medicine is listed.
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017, reflecting a ~17% YoY (year-over-year) growth. It reported net revenues of $746.3 million in the first half of 2018 compared to $621.2 million in the first half of 2017, reflecting a ~2% YoY growth.
On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6.
Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) Abbott Laboratories (NYSE: ...
Vertex Pharmaceuticals Incorporated (VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and patient stratification in diseases with significant unmet need. The goal of the collaboration is to further advance Vertex’s efforts to develop transformative precision medicines for people with serious diseases.